Maykin Ho - May 28, 2025 Form 4 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Director
Signature
/s/ Michael Milligan, as Attorney-in-Fact for Maykin Ho
Stock symbol
NMRA
Transactions as of
May 28, 2025
Transactions value $
$0
Form type
4
Date filed
5/30/2025, 06:30 PM
Previous filing
May 22, 2025
Next filing
Jun 6, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ho Maykin Director C/O NEUMORA THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 200, WATERTOWN /s/ Michael Milligan, as Attorney-in-Fact for Maykin Ho 2025-05-30 0001646395

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -95.6K -100% 0 May 28, 2025 Common Stock 95.6K $1.69 Direct F1, F2
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -27.8K -100% 0 May 28, 2025 Common Stock 27.8K $1.69 Direct F1, F2
transaction NMRA Stock Option (Right to Buy) Disposed to Issuer -28.6K -100% 0 May 28, 2025 Common Stock 28.6K $1.69 Direct F1, F2
transaction NMRA Stock Option (Right to Buy) Award +95.6K 95.6K May 28, 2025 Common Stock 95.6K $0.72 Direct F1, F2, F3
transaction NMRA Stock Option (Right to Buy) Award +27.8K 27.8K May 28, 2025 Common Stock 27.8K $0.72 Direct F1, F2, F3
transaction NMRA Stock Option (Right to Buy) Award +28.6K 28.6K May 28, 2025 Common Stock 28.6K $0.72 Direct F1, F2, F3
transaction NMRA Stock Option (Right to Buy) Award $0 +80K $0.00 80K May 28, 2025 Common Stock 80K $0.72 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option is fully vested and exercisable.
F2 On May 28, 2025, the Issuer's stockholders approved the repricing of the option. As further described in footnote 3, all other terms of the option remain unchanged.
F3 On May 28, 2025, the Issuer's stockholders approved an option repricing at an exercise price of $0.72 per share (the "Repricing") of the outstanding stock options held by members of the Board, certain employees and other service providers. The Repricing is subject to the Reporting Person remaining in service to the Issuer through August 13, 2026.
F4 100% of the shares subject to the option vest on the earlier of (i) the one year anniversary of May 28, 2025 or (ii) immediately prior to the next Annual Meeting following May 28, 2025.